MORRISVILLE, N.C., August 18, 2026
Syneos Health announced continued expansion of its AI-powered clinical development ecosystem, bringing together artificial intelligence, scientific expertise, healthcare professional intelligence and connected data to improve clinical trial performance and accelerate decision-making. The fully integrated biopharmaceutical solutions organization is embedding AI capabilities into critical stages of clinical development, including protocol design, feasibility planning, patient enrollment, site activation, clinical monitoring and operational oversight. By applying AI at key decision points, Syneos Health aims to help biopharmaceutical sponsors identify operational risks earlier, reduce workflow complexity and make faster, more informed decisions throughout the clinical trial lifecycle.
AI Integration Targets Critical Clinical Trial Decisions
Syneos Health’s AI strategy focuses on integrating technology directly into the complex workflows that influence clinical trial execution and performance. Rather than treating AI as a standalone technology, the company is combining AI-enabled tools with decades of therapeutic, clinical and commercial experience. This approach is designed to help sponsors improve predictability and operational efficiency while maintaining appropriate human oversight in regulated environments. AI capabilities are being applied across protocol strategy, feasibility assessments, enrollment planning, site activation, monitoring and clinical operations. Syneos Health says this integrated approach can help teams anticipate potential problems earlier and respond more quickly as trials progress. The company’s goal is to improve study performance while supporting faster development of therapies for patients.
Causaly, Databricks and Microsoft Expand AI Capabilities
Syneos Health is strengthening its AI ecosystem through collaborations with Causaly, Databricks and Microsoft, creating an interconnected environment for scientific intelligence, clinical data and AI-enabled execution. Through its collaboration with Causaly, Syneos Health is applying agentic, evidence-based scientific reasoning to protocol strategy, feasibility planning and competitive trial intelligence. Causaly’s technology uses a biomedical knowledge graph to analyze scientific and commercial information, and Syneos Health reports that its teams have reduced the time required to derive insights for study strategy and design by approximately 50%. With Databricks, Syneos Health is developing a unified intelligence environment that combines operational, clinical and real-world data. The company says the resulting near-real-time view of clinical operations can reduce the time between source data capture and review-ready insight from days to hours, allowing teams to identify issues and intervene more rapidly. Syneos Health is also expanding its long-standing collaboration with Microsoft, using Microsoft Power Apps and related technologies to develop more than 280 AI agents integrated with Microsoft 365 Copilot to streamline workflows and support employee productivity and decision-making.
Advertisement
Governed AI Supports Faster Clinical Development
The expanded ecosystem combines external AI platforms with proprietary Syneos Health insights and agentic AI solutions embedded within clinical workflows. These capabilities are designed to reduce operational complexity, improve trial predictability and support more scalable clinical development processes. Importantly, Syneos Health emphasizes that AI deployment is supported by human oversight and governance, an essential consideration when applying artificial intelligence within regulated clinical research environments. By connecting scientific evidence, operational data and clinical expertise, the company aims to help sponsors make more precise decisions across the development lifecycle. The broader adoption of AI in clinical research could help address persistent challenges such as complex protocols, site performance, patient recruitment, monitoring and rapidly changing clinical data. Syneos Health’s approach reflects a growing shift toward AI-enabled clinical trial operations, where technology is increasingly being integrated into everyday development workflows rather than used only for isolated analytical tasks. As pharmaceutical and biotechnology companies seek to improve trial efficiency and accelerate development timelines, governed AI ecosystems could become increasingly important to the future of clinical research and biopharmaceutical development.
Source: Syneos Health press relese
